192 related articles for article (PubMed ID: 35765281)
1. Absolute lymphocyte count and C-reactive protein-albumin ratio can predict prognosis and adverse events in patients with recurrent esophageal cancer treated with nivolumab therapy.
Inoue H; Shiozaki A; Fujiwara H; Konishi H; Kiuchi J; Ohashi T; Shimizu H; Arita T; Yamamoto Y; Morimura R; Kuriu Y; Ikoma H; Kubota T; Okamoto K; Otsuji E
Oncol Lett; 2022 Aug; 24(2):257. PubMed ID: 35765281
[TBL] [Abstract][Full Text] [Related]
2. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
[TBL] [Abstract][Full Text] [Related]
3. Predictive Impact of Peripheral Blood Markers and C-Reactive Protein in Nivolumab Therapy for Metastatic Renal Cell Carcinoma.
Ishihara H; Tachibana H; Takagi T; Kondo T; Fukuda H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
Target Oncol; 2019 Aug; 14(4):453-463. PubMed ID: 31359231
[TBL] [Abstract][Full Text] [Related]
4. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment absolute lymphocyte count is an independent predictor for survival outcomes for esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy and pembrolizumab: An analysis from a prospective cohort.
Qi WX; Wang X; Li C; Li S; Li H; Xu F; Chen J; Zhao S; Li H
Thorac Cancer; 2023 Jun; 14(17):1556-1566. PubMed ID: 37089116
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Significance of Pretreatment Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, or Monocyte-to-Lymphocyte Ratio in Endometrial Neoplasms: A Systematic Review and Meta-analysis.
Leng J; Wu F; Zhang L
Front Oncol; 2022; 12():734948. PubMed ID: 35651788
[TBL] [Abstract][Full Text] [Related]
7. Absolute Lymphocyte Count, Platelet-to-Lymphocyte Ratio, and Overall Survival in Eribulin-treated HER2-negative Metastatic Breast Cancer Patients.
Koyama Y; Kawai S; Uenaka N; Okazaki M; Asaoka M; Teraoka S; Ueda AI; Miyahara K; Kawate T; Kaise H; Yamada K; Ishikawa T
Cancer Diagn Progn; 2021; 1(5):435-441. PubMed ID: 35403160
[TBL] [Abstract][Full Text] [Related]
8. Post-treatment Neutrophil/Lymphocyte Ratio Is a Prognostic Factor in Head and Neck Cancers Treated With Nivolumab.
Iwasa YI; Kitoh R; Yokota Y; Hori K; Kasuga M; Kobayashi T; Kanda S; Takumi Y
Cancer Diagn Progn; 2024; 4(2):182-188. PubMed ID: 38434918
[TBL] [Abstract][Full Text] [Related]
9. Association between platelet-to-lymphocyte ratio and outcomes in HER2-positive advanced breast cancer patients treated with pyrotinib: a retrospective study.
Hao L; Dong J; Yu H; Chen J; Han X; Pan Y
Transl Cancer Res; 2023 Oct; 12(10):2726-2741. PubMed ID: 37969380
[TBL] [Abstract][Full Text] [Related]
10. [Effect of preoperative monocyte-lymphocyte ratio on prognosis of patients with resectable esophagogastric junction cancer].
Zhou WJ; Wu J; Li XD; Wang Q; Ni XF; Jiang JT; Ji M; Wu CP
Zhonghua Zhong Liu Za Zhi; 2017 Mar; 39(3):178-183. PubMed ID: 28316215
[No Abstract] [Full Text] [Related]
11. Changes in neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios during chemoradiation predict for survival and pathologic complete response in trimodality esophageal cancer patients.
Hyder J; Boggs DH; Hanna A; Suntharalingam M; Chuong MD
J Gastrointest Oncol; 2016 Apr; 7(2):189-95. PubMed ID: 27034785
[TBL] [Abstract][Full Text] [Related]
12. Clinical utility of the C-reactive protein:albumin ratio in non-small cell lung cancer patients treated with nivolumab.
Araki T; Tateishi K; Sonehara K; Hirota S; Komatsu M; Yamamoto M; Kanda S; Kuraishi H; Hanaoka M; Koizumi T
Thorac Cancer; 2021 Mar; 12(5):603-612. PubMed ID: 33434414
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of preoperative inflammatory response biomarkers in patients with esophageal cancer who undergo a curative thoracoscopic esophagectomy.
Hirahara N; Matsubara T; Mizota Y; Ishibashi S; Tajima Y
BMC Surg; 2016 Sep; 16(1):66. PubMed ID: 27650456
[TBL] [Abstract][Full Text] [Related]
14. Predictive impact of C-reactive protein to albumin ratio for recurrent or metastatic head and neck squamous cell carcinoma receiving nivolumab.
Tanoue K; Tamura S; Kusaba H; Shinohara Y; Ito M; Tsuchihashi K; Shirakawa T; Otsuka T; Ohmura H; Isobe T; Ariyama H; Koreishi S; Matsushita Y; Shimokawa H; Tanaka R; Mitsugi K; Akashi K; Baba E
Sci Rep; 2021 Feb; 11(1):2741. PubMed ID: 33531609
[TBL] [Abstract][Full Text] [Related]
15. Combination of preoperative neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and monocyte-lymphocyte ratio: a superior prognostic factor of endometrial cancer.
Cong R; Kong F; Ma J; Li Q; Wu Q; Ma X
BMC Cancer; 2020 May; 20(1):464. PubMed ID: 32448185
[TBL] [Abstract][Full Text] [Related]
16. Can Neutrophil-to-Lymphocyte Ratio, Monocyte-to-Lymphocyte Ratio, and Platelet-to-Lymphocyte Ratio at Day +100 be used as a prognostic marker in Multiple Myeloma patients with autologous transplantation?
Solmaz Medeni S; Acar C; Olgun A; Acar A; Seyhanlı A; Taskıran E; Sevindik OG; Alacacıoglu I; Piskin O; Ozcan MA; Demirkan F; Undar B; Ozsan GH
Clin Transplant; 2018 Sep; 32(9):e13359. PubMed ID: 30053318
[TBL] [Abstract][Full Text] [Related]
17. Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma.
Dharmapuri S; Özbek U; Jethra H; Jun T; Marron TU; Saeed A; Huang YH; Muzaffar M; Pinter M; Balcar L; Fulgenzi C; Amara S; Weinmann A; Personeni N; Scheiner B; Pressiani T; Navaid M; Bengsch B; Paul S; Khan U; Bettinger D; Nishida N; Mohamed YI; Vogel A; Gampa A; Korolewicz J; Cammarota A; Kaseb A; Galle PR; Pillai A; Wang YH; Cortellini A; Kudo M; D'Alessio A; Rimassa L; Pinato DJ; Ang C
World J Gastrointest Oncol; 2023 Nov; 15(11):1900-1912. PubMed ID: 38077640
[TBL] [Abstract][Full Text] [Related]
18. Monocyte-to-lymphocyte ratio as a prognostic factor in peripheral whole blood samples of colorectal cancer patients.
Jakubowska K; Koda M; Grudzińska M; Kańczuga-Koda L; Famulski W
World J Gastroenterol; 2020 Aug; 26(31):4639-4655. PubMed ID: 32884222
[TBL] [Abstract][Full Text] [Related]
19. Inflammation-based Prognostic Score as a Prognostic Biomarker in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Treated With Nivolumab Therapy.
Matsuo M; Yasumatsu R; Masuda M; Toh S; Wakasaki T; Hashimoto K; Jiromaru R; Manako T; Nakagawa T
In Vivo; 2022; 36(2):907-917. PubMed ID: 35241549
[TBL] [Abstract][Full Text] [Related]
20. Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients.
Khunger M; Patil PD; Khunger A; Li M; Hu B; Rakshit S; Basu A; Pennell N; Stevenson JP; Elson P; Panchabhai TS; Velcheti V
PLoS One; 2018; 13(10):e0197743. PubMed ID: 30359383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]